11 February 2019

FDA APPROVES OCTIMET'S NEW DRUG APPLICATION

One of our clients, OCTIMET Oncology NV, a biotech spin off company focusing on the development of highly specific and differentiated oral MET kinase inhibitors, announces the approval of its application to evaluate OMO-1.
OCTIMET licensed three patent families related to highly selective MET kinase inhibitors, and has its current focus on its clinical stage lead asset OMO-1, a highly selective small molecule MET kinase inhibitor that is developed using specific patient selection biomarkers.
Based on the high combination potential inherent to OMO-1 and known MET pharmacology, additional opportunities for significantly increasing market size exist in a range of indications with a defined set of biomarker selected, combination partners.